AstraZeneca Q1 sales rise 8% to $15.3 B, oncology up 16%
AstraZeneca reported Q1 sales of $15.3 billion, up 8%, with oncology revenue at $6.8 billion growing 16% driven by Imfinzi, Tagrisso, Calquence and Enhertu. The company reiterated full-year revenue and earnings guidance despite headwinds from Farxiga and Brilinta patent expiries in the US, UK and China, and remains on track for $80 billion by 2030.
1. Q1 Financial Performance
AstraZeneca posted first-quarter sales of $15.3 billion, marking an 8% year-over-year increase driven by robust demand across multiple therapeutic areas.
2. Oncology Portfolio Performance
Oncology accounted for $6.8 billion of revenue and grew 16%, with key products Imfinzi, Tagrisso, Calquence and Enhertu delivering strong market uptake.
3. Patent Expiries Create Headwinds
The company faces significant patent losses for Brilinta in the US and Farxiga in the US, UK and China, adding pressure to its cardiovascular franchise.
4. Pipeline Outlook and Guidance
Management reiterated full-year revenue and earnings targets, highlighted upcoming oncology and hematology approvals, and affirmed its goal of reaching $80 billion in sales by 2030.